Baird Initiates Coverage On TransMedics Gr with Outperform Rating, Announces Price Target of $200
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joe Vruwink has initiated coverage on TransMedics Group (NASDAQ:TMDX) with an Outperform rating and set a price target of $200.
September 24, 2024 | 10:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Joe Vruwink has initiated coverage on TransMedics Group with an Outperform rating and a price target of $200, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating and a high price target suggests a strong positive sentiment from Baird, likely leading to increased investor interest and potential upward movement in TMDX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100